On page 6, line 24, after "TNF-beta," insert -- (SEQ ID\NO:14) --

On page 6, line 24, after "LT-alpha," insert -- (SEQ ID NO:15) --

On page 6, line 24, after "CD40L," insert -- (SEQ ID NO:16) --.

On page 6, line 24, after "Apo-1L," insert - (Seq ID NO:17) --.

On page 41, line 1, delete "Rockville, Maryland" and insert -- Manassas, Virginia --.

On page 50, line 3, delete "Rockville, Maryland" and insert -- Manassas, Virginia --.

On page 66, lines 4-5, delete "12301 Parklawn Drive, Rockville, MD" and insert -- 10801 University Boulevard, Manassas, Virginia --.

## In the Claims:

Please cancel without prejudice claims 1-23 and 26-29.

24. (Amended) A method of treating a mammal having <u>cervical</u> cancer, comprising administering to [a] the mammal [diagnosed as having cancer an effective amount of Apo-2 ligand] <u>Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.</u>

Please add the following claims:

- -- 30. The method of claim 24 wherein radiation therapy or chemotherapy is further administered to the mammal.
- 31. The method of claim 30 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.
- 32. The method of claim 30 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

And the second of the second o

the state of


ij 17



- 33. The method of claim \24 wherein the Apo-2 ligand polypeptide is selected from the group:
- a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);
- a polypeptide comprising a fragment or variant of (a); and (b)
- (C) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).
- 34. The method of claim 24 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.
- 35. A method of treating a mamma having bladder cancer, comprising administering to the mammal Apo-2\ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.
- 36. The method of claim 35 wherein \radiation therapy or chemotherapy is further administered to the mammal.
- 37. The method of claim 36 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.
- 38. The method of claim 36 wherein the chemotherapy is selected from the group consisting of Doxorubicin, \$-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.
- 39. The method of claim 35 wherein the Apo-2 ligand polypeptide is selected from the group:
- a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);
- (b) a polypeptide comprising a fragment or variant of (a); and

- (c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).
- 40. The method of claim 35 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.
- 41. A method of treating a mammal having neuroblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.
- 42. The method of claim 41 wherein radiation therapy or chemotherapy is further administered to the mammal.
- 43. The method of claim 42 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.
- 44. The method of claim 42 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.
- 45. The method of claim 41 wherein the Apo-2 ligand polypeptide is selected from the group:
- (a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);
- (b) a polypeptide comprising a fragment or variant of (a); and
- (c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).
- 46. The method of claim 41 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group





- 47. A method of treating a mammal having glioma or glioblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioma or glioblastoma cells.
- 48. The method of claim 47 wherein radiation therapy or chemotherapy is further administered to the mammal.
- 49. The method of claim 48 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.
- 50. The method of claim 48 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.
- 51. The method of claim 47 wherein the Apo-2 ligand polypeptide is selected from the group;
- (a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);
- (b) a polypeptide comprising a fragment or variant of (a); and
- (c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).
- 52. The method of claim 47 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.